In the quarterly meeting of the General Assembly of PanACEA on 23rd of September an update was given on the progress of the trials and the capacity development plans. The operational teams and study teams are working hard for the final preparations of the BTZ043 trial that will start in November of 2019. This phase 1A/1B trial will assess the safety/tolerability and bactericidal activity of the novel TB drug BTZ043. Preparations for the SUDOCU study are also well under way. This phase IIB trial is scheduled to start in Q2 of 2020 and will assess the optimal dose of sutezolid for larger follow-up studies.
PanACEA General Assembly
